https://www.selleckchem.com/pr....oducts/cepharanthine
Herein we present an overview of the infrastructure of producing 211At radiopharmaceuticals, from target to radiolabeled product including chemical strategies to overcome hurdles for advancement into clinical trials with 211At.Background Long noncoding RNAs could serve as a candidate target for prostate cancer (PCa) diagnosis and treatment. The current study aimed to investigate the role and functions of SNHG1 in PCa cells. Materials and Methods Abnormal expression of SNHG1, survival analysis, and target gene were determined or pr
Like
Comment
Share
